FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089249991> ?p ?o ?g. }

• W3089249991 endingPage "e2013565" @default.
• W3089249991 startingPage "e2013565" @default.
• W3089249991 abstract "<h3>Importance</h3> Gastrointestinal stromal tumor (GIST) is frequently driven by oncogenic<i>KIT</i>variations. Imatinib targeting of<i>KIT</i>marked a new era in GIST treatment and ushered in precision oncological treatment for all solid malignant neoplasms. However, studies on the molecular biological traits of GIST have found that tumors respond differentially to imatinib dosage based on the<i>KIT</i>exon with variation. Despite this knowledge, few patients undergo genetic testing at diagnosis, and empirical imatinib therapy remains routine. Barriers to genetic profiling include concerns about the cost and utility of testing. <h3>Objective</h3> To determine whether targeted gene testing (TGT) is a cost-effective diagnostic for patients with metastatic GIST from the US payer perspective. <h3>Design, Setting, and Participants</h3> This economic evaluation developed a Markov model to compare the cost-effectiveness of TGT and tailored first-line therapy compared with empirical imatinib therapy among patients with a new diagnosis of metastatic GIST. The main health outcome, quality-adjusted life years (QALYs), and costs were obtained from the literature, and transitional probabilities were modeled from disease progression and survival estimates from randomized clinical trials of patients with metastatic GIST. Data analyses were conducted October 2019 to January 2020. <h3>Exposure</h3> TGT and tailored first-line therapy. <h3>Main Outcomes and Measures</h3> The primary outcome was QALYs and cost. Cost-effectiveness was defined using an incremental cost-effectiveness ratio, with an incremental cost-effectiveness ratio less than $100 000/QALY considered cost-effective. One-way and probabilistic sensitivity analyses were conducted to assess model stability. <h3>Results</h3> Therapy directed by TGT was associated with an increase of 0.10 QALYs at a cost of $9513 compared with the empirical imatinib approach, leading to an incremental cost-effectiveness ratio of $92 100. These findings were sensitive to the costs of TGT, drugs, and health utility model inputs. Therapy directed by TGT remained cost-effective for genetic testing costs up to $3730. Probabilistic sensitivity analysis found that TGT-directed therapy was considered cost-effective 70% of the time. <h3>Conclusions and Relevance</h3> These findings suggest that using genetic testing to match treatment of<i>KIT</i>variations to imatinib dosing is a cost-effective approach compared with empirical imatinib." @default.
• W3089249991 created "2020-10-01" @default.
• W3089249991 creator A5003994815 @default.
• W3089249991 creator A5005618779 @default.
• W3089249991 creator A5008180849 @default.
• W3089249991 creator A5024070075 @default.
• W3089249991 creator A5043763331 @default.
• W3089249991 creator A5059074865 @default.
• W3089249991 creator A5061839315 @default.
• W3089249991 creator A5064099533 @default.
• W3089249991 creator A5068337938 @default.
• W3089249991 date "2020-09-28" @default.
• W3089249991 modified "2023-10-12" @default.
• W3089249991 title "Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors" @default.
• W3089249991 cites W1741335535 @default.
• W3089249991 cites W1820078379 @default.
• W3089249991 cites W1967229780 @default.
• W3089249991 cites W2013206413 @default.
• W3089249991 cites W2014943657 @default.
• W3089249991 cites W2015015957 @default.
• W3089249991 cites W2030379493 @default.
• W3089249991 cites W2055230209 @default.
• W3089249991 cites W2068079378 @default.
• W3089249991 cites W2071056007 @default.
• W3089249991 cites W2088300894 @default.
• W3089249991 cites W2099067205 @default.
• W3089249991 cites W2100722947 @default.
• W3089249991 cites W2108431450 @default.
• W3089249991 cites W2110509198 @default.
• W3089249991 cites W2116922255 @default.
• W3089249991 cites W2129093214 @default.
• W3089249991 cites W2139511378 @default.
• W3089249991 cites W2169363650 @default.
• W3089249991 cites W2175901504 @default.
• W3089249991 cites W2206652173 @default.
• W3089249991 cites W2416704090 @default.
• W3089249991 cites W2517396491 @default.
• W3089249991 cites W2519603001 @default.
• W3089249991 cites W2552016347 @default.
• W3089249991 cites W2565222838 @default.
• W3089249991 cites W2608457900 @default.
• W3089249991 cites W2737446049 @default.
• W3089249991 cites W2739896399 @default.
• W3089249991 cites W2767051969 @default.
• W3089249991 cites W2782077264 @default.
• W3089249991 cites W2788468983 @default.
• W3089249991 cites W2923168788 @default.
• W3089249991 cites W3010719773 @default.
• W3089249991 cites W4237752811 @default.
• W3089249991 cites W4238208852 @default.
• W3089249991 cites W4250250581 @default.
• W3089249991 cites W4285097283 @default.
• W3089249991 cites W4376848385 @default.
• W3089249991 cites W2944320945 @default.
• W3089249991 doi "https://doi.org/10.1001/jamanetworkopen.2020.13565" @default.
• W3089249991 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7522695" @default.
• W3089249991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32986105" @default.
• W3089249991 hasPublicationYear "2020" @default.
• W3089249991 type Work @default.
• W3089249991 sameAs 3089249991 @default.
• W3089249991 citedByCount "13" @default.
• W3089249991 countsByYear W30892499912021 @default.
• W3089249991 countsByYear W30892499912022 @default.
• W3089249991 countsByYear W30892499912023 @default.
• W3089249991 crossrefType "journal-article" @default.
• W3089249991 hasAuthorship W3089249991A5003994815 @default.
• W3089249991 hasAuthorship W3089249991A5005618779 @default.
• W3089249991 hasAuthorship W3089249991A5008180849 @default.
• W3089249991 hasAuthorship W3089249991A5024070075 @default.
• W3089249991 hasAuthorship W3089249991A5043763331 @default.
• W3089249991 hasAuthorship W3089249991A5059074865 @default.
• W3089249991 hasAuthorship W3089249991A5061839315 @default.
• W3089249991 hasAuthorship W3089249991A5064099533 @default.
• W3089249991 hasAuthorship W3089249991A5068337938 @default.
• W3089249991 hasBestOaLocation W30892499911 @default.
• W3089249991 hasConcept C112930515 @default.
• W3089249991 hasConcept C121608353 @default.
• W3089249991 hasConcept C126322002 @default.
• W3089249991 hasConcept C143998085 @default.
• W3089249991 hasConcept C16930146 @default.
• W3089249991 hasConcept C2775922572 @default.
• W3089249991 hasConcept C2777007597 @default.
• W3089249991 hasConcept C2777583451 @default.
• W3089249991 hasConcept C2778729363 @default.
• W3089249991 hasConcept C2780673598 @default.
• W3089249991 hasConcept C2781230642 @default.
• W3089249991 hasConcept C3019080777 @default.
• W3089249991 hasConcept C64332521 @default.
• W3089249991 hasConcept C71924100 @default.
• W3089249991 hasConceptScore W3089249991C112930515 @default.
• W3089249991 hasConceptScore W3089249991C121608353 @default.
• W3089249991 hasConceptScore W3089249991C126322002 @default.
• W3089249991 hasConceptScore W3089249991C143998085 @default.
• W3089249991 hasConceptScore W3089249991C16930146 @default.
• W3089249991 hasConceptScore W3089249991C2775922572 @default.
• W3089249991 hasConceptScore W3089249991C2777007597 @default.
• W3089249991 hasConceptScore W3089249991C2777583451 @default.
• W3089249991 hasConceptScore W3089249991C2778729363 @default.

• next